Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax

To get its hands on the Emeryville, California-based company and its approved adult hepatitis B vaccine Heplisav-B, Sanofi will pay $15.50 per Dynavax share in cash, which works out to a total deal value of roughly $2.2 billion.